Development of solid self-nanoemulsifying granules (SSNEGs) of ondansetron hydrochloride with enhanced bioavailability potential

Colloids and Surfaces B: Biointerfaces

Volumn 101, Issue , 2013, Pages 414-423

  Beg, Sarwar ^a,c   Jena, Sidharth Sankar ^a   Patra, Ch Niranjan ^a   Rizwan, Mohammad ^b   Swain, Suryakanta ^a   Sruti, J ^a   Rao, M E Bhanoji ^a   Singh, Bhupinder ^c  

^a Roland Institute of Pharmaceutical Sciences   (India)

^b Wockhardt Research Center   (India)

^c PANJAB UNIVERSITY   (India)

Author keywords

Hepatic first pass effect; Pharmacokinetics; Porous carriers; Self nanoemulsifying; SNEDDS

Indexed keywords

AQUEOUS SOLUBILITY; CO-SURFACTANTS; DISPERSIBILITIES; DROPLET SIZES; FREE FLOWING; FTIR; HEPATIC FIRST-PASS EFFECT; IN-VITRO; IN-VIVO; NANOEMULSION; POWDER XRD; PSEUDOTERNARY PHASE DIAGRAMS; SELF-NANOEMULSIFYING; SNEDDS; SOLID STATE CHARACTERIZATION; TWEEN-20; WISTAR RAT;

ADSORPTION; BIOCHEMISTRY; DRUG INTERACTIONS; EMULSIFICATION; GRANULATION; OPTIMIZATION; PHARMACOKINETICS; PHASE DIAGRAMS; REFRACTIVE INDEX; SOLUBILITY; ZETA POTENTIAL;

LIQUIDS;

ALUMINUM SILICATE; ATTAPULGITE; EXCIPIENT; LABRASOL; OCTANOIN; ONDANSETRON; POLYSORBATE 20; SILICON DIOXIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG GRANULE; DRUG MIXTURE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; IN VITRO STUDY; LYMPHATIC SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; POROSITY; PREFORMULATION; PRIORITY JOURNAL; RAT; REACTION OPTIMIZATION; REACTION TIME; SOLID SELF NANOEMULSIFYING GRANULE; SOLID STATE; THERMODYNAMICS; VISCOSITY; ZETA POTENTIAL;

ANIMALS; ANTIEMETICS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; EXCIPIENTS; FEMALE; LIVER; LYMPHATIC SYSTEM; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; ONDANSETRON; P-GLYCOPROTEIN; RATS; RATS, WISTAR; REFRACTOMETRY; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; THERMODYNAMICS; VISCOSITY; X-RAY DIFFRACTION;

RATTUS NORVEGICUS;

EID: 84865568713     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.06.031     Document Type: Article

References (57)

1. Pouton C.W. Eur. J. Pharm. Sci. 2006, 29:278.
2. Beg S., Swain S., Rizwan M., Irfanuddin M., Malini D.S. Curr. Drug. Deliv. 2011, 8:691.
3. Gattefosse [Online]. (accessed on 08.06.12). http://www.gattefosse.com/en/self-emulsifying-lipid-formulation/.
4. Baboota S., Agarwal S.P. Pharmazie 2003, 58:73.
5. Ahuja N., Katare O.P., Singh B. Eur. J. Pharm. Biopharm. 2007, 65:26.
6. Krishnaiah Y.S.R J. Bioequival. Bioavail. 2010, 2:28.
7. Kang M.J., Cho J.Y., Shim B.H., Kim D.K., Lee J. J. Med. Plants Res. 2009, 3:1204.
8. Muller R.H., Jacobs C., Kayser O. Adv. Drug Deliv. Rev. 2001, 47:3.
9. Singh B., Rani A., Garg B., Ahuja N., Kapil R. Sci. Pharm. 2010, 78:303.
10. Patravale V.B., Date A.A., Kulkarni R.M. J. Pharm. Pharmacol. 2004, 56:827.
11. Milhem O.M., Myles C., McKeown N.B., Attwood D., D'Emanuele A. Int. J. Pharm. 2000, 197:239.
12. Beg S., Rizwan M., Sheikh A.M., Hasnain M.S., Anwer K., Kohli K. J. Pharm. Pharmacol. 2011, 63:141.
13. Gershanik T., Benita S. Eur. J. Pharm. Biopharm. 2000, 50:179.
14. Ondansetron Hydrochloride, Drugs.com [Online]. (accessed on 06.06.12). http://www.drugs.com/ppa/ondansetron-hydrochloride.html.
15. DrugBank, Open data drug and Drug target database [Online]. (accessed on 07.06.12). http://drugbank.ca/drugs/DB00904.
16. Yang S.H., Lee M.G. J. Pharm. Pharmacol. 2008, 60:853.
17. Koland M., Sandeep V.P., Charyulu N.R. J. Young Pharm. 2010, 2:216.
18. Cho E., Gwak H., Chun I. Int. J. Pharm. 2008, 349:101.
19. Hassan N., Khar R.K., Ali M., Ali J. AAPS PharmSciTech 2009, 10:1085.
20. Singh B., Bandopadhyay S., Kapil R., Singh R., Katare O.P. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26:427.
21. Pouton C.W. Adv. Drug Deliv. Rev. 1997, 25:47.
22. Gursoy R.N., Benita S. Biomed. Pharmacother. 2004, 58:173.
23. Singh B., Khurana L., Bandyopadhyay S., Kapil R., Katare O.P. Drug Deliv. 2011, 18:599.
24. Yi T., Wan J., Xu H., Yang X. Eur. J. Pharm. Biopharm. 2008, 70:439.
25. S. Faucher, R. Carlini, J. Chung, US2010/0316946; 2010.
26. S. Booth, A. Clarke, J. Newton, US6630150 (2001).
27. Nazzal S., Khan M.A. AAPS PharmSciTech 2002, 3:E3.
28. Tang B.G., Cheng G., Gu J.-C., Xu C.-H. Drug Discov. Today 2008, 13:606.
29. Dixit R.P., Nagarsenker M.S. Eur. J. Pharm. Sci. 2008, 35:183.
30. Patil P., Joshi P., Paradkar A. AAPS PharmSciTech 2004, 5:e42.
31. Kang M.J., Jung S.Y., Song W.H., Park J.S., Choi S.U., Oh K.T., Choi H.K., Choi Y.W., Lee J., Lee B.J., Chi S.C. Drug Dev. Ind. Pharm. 2011, 37:1298.
32. Takeuchi H., Nagira S., Yamamoto H., Kawashima Y. Int. J. Pharm. 2005, 293:155.
33. Uchino T., Yasuno N., Yanagihara Y., Suzuki H. Pharmazie 2007, 62:599.
34. Dissolution methods database [Online]. (accessed on 31.05.12). http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm.
35. Gosh M.N. Fundamentals of Experimental Pharmacology 2007, vol. 39. Hilton and Company Publishers, Kolkata.
36. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Cancer Chemother. Rep. 1996, 50:219.
37. Liu J., Stewart J.T. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 694:179.
38. Kommuru T.R., Gurley B., Khan M.A., Reddy I.K. Int. J. Pharm. 2001, 212:233.
39. Fuji Sylysia, Sylysia FCP, Fuji Chemical Industries [Online]. (accessed on 05.06.12). http://www.tcrindustries.com/Principals/BROCHURES/fujibrochures/FCP%20Brochure.pdf.
40. Neusilin [Online]. (accessed on 08.06.12). http://www.neusilin.com/.
41. Porter C.J.H, Trevaskis N.L., Charman W.N. Nat. Rev. Drug Discov. 2007, 6:231.
42. Chakraborty S., Shukla D., Mishra B., Singh S. Eur. J. Pharm. Biopharm. 2009, 73:1.
43. S. Bandyopadhyay, O.P. Katare, B. Singh, Colloids Surf. B Biointerfaces, in press, doi.org/10.1016/j.bbr.2011.03.031.
44. Dixit A.R., Rajput S.J., Patel S.G. AAPS PharmSciTech 2010, 11:314.
45. Parmar N., Singla N., Amin S., Kohli K. Colloids Surf. B Biointerfaces 2011, 86:327.
46. Biradar S.V., Dhumal R.S., Paradkar A. J. Pharm. Pharm. Sci. 2009, 12:17.
47. Rizwan M., Aqil M., Azeem A., Talegaonkar S., Sultana Y., Ali A. J. Exp. Nanosci. 2010, 5:390.
48. Kohli K., Chopra S., Dhar D., Arora S., Khar R.K. Drug Discov. Today 2010, 15:958.
49. Lee B.J., On D.H., Kim J.O., Hong M.J., Jee J.P., Kim J.A., You B.K., Wo J.S., Yong C.S., Choi H.G. Eur. J. Pharm. Biopharm. 2009, 72:539.
50. Wang L., Cui F.D., Sunada H. Chem. Pharm. Bull. 2006, 54:37.
51. Ito Y., Arai H., Uchino K., Iwasaki K., Shibata N., Takada K. Int. J. Pharm. 2005, 289:69.
52. Ahuja G., Pathak K. Ind. J. Pharm. Sci. 2009, 71:599.
53. Patil P., Paradkar A. AAPS PharmSciTech 2006, 7:E28.
54. Sander C., Holm P. AAPS PharmSciTech 2009, 10:1388.
55. SYLYSIA FC, Fuji Sylysia [Online]. (accessed on 08.06.12). http://www.tcrindustries.com/Principals/BROCHURES/fujibrochures/FCP%20Brochure.pdf.
56. Bhatt S., Trivedi P. J. Chem. Pharm. Res. 2011, 3:472.
57. Taha E.I. Sci. Pharm. 2009, 77:443.